OC
RXST icon

Oppenheimer & Co’s RxSight RXST Stock Holding History

Oppenheimer & Co’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,880
Closed -$202K – 1651
2024
Q4 		$202K Sell
5,880
-219
-4% -$9.88K ﹤0.01% 1454
2024
Q3 		$301K Buy
6,099
+823
+16% +$42.2K ﹤0.01% 1228
2024
Q2 		$317K Sell
5,276
-1,772
-25% -$101K 0.01% 1170
2024
Q1 		$364K Buy
+7,048
New +$346K 0.01% 1109

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Oppenheimer & Co's RXST Position: Q1 2025 in Review

Oppenheimer & Co sold out of RxSight (RXST) in Q1 2025, closing a stake of 5,880 shares — an estimated $202K sold.

Oppenheimer & Co first reported a position in RXST in Q1 2024 and held it in 4 quarters. The position peaked at $364K in Q1 2024. 192 funds tracked by Wall St. Rank hold RXST as of Q1 2025.

  • Oppenheimer & Co reported no remaining RxSight position as of Q1 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 5,880 RxSight shares in Q1 2025, an estimated $202K.
  • Oppenheimer & Co first reported a position in RxSight in Q1 2024 and held it in 4 quarters.
  • Oppenheimer & Co's RxSight position peaked at $364K in Q1 2024.
  • 192 funds tracked by Wall St. Rank held RxSight as of Q1 2025.

Based on Oppenheimer & Co's 13F filing for Q1 2025, filed 23 Apr 2025.